Global Musculoskeletal Partnering 2012-2018: Updated Deal Trends, Players and Financials - Access to Headline, Upfront, Milestone and Royalty Data - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Global Musculoskeletal Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
The Global Musculoskeletal Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.
The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scopeTrends in Musculoskeletal dealmaking in the biopharma industry since 2012 Analysis of Musculoskeletal deal structure Access to headline, upfront, milestone and royalty data The leading Musculoskeletal deals by value since 2012
Available deals are listed by:Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Musculoskeletal dealmaking
Chapter 3 - Financial deal terms for Musculoskeletal partnering
Chapter 4 - Leading Musculoskeletal deals and dealmakers
Chapter 5 - Musculoskeletal contract document directory
Chapter 6 - Musculoskeletal dealmaking by therapeutic targetFor more information about this report visit https://www.researchandmarkets.com/research/2lhfvs/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918006103/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/18/2018 04:49 PM/DISC: 09/18/2018 04:49 PM